Superior vena cava syndrome: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 24: Line 24:
== Overview ==
== Overview ==


'''Superior vena cava (SVC) syndrome''' is the obstruction of the superior vena cava resulting in diminished venous return from the head, neck and upper extremities.  
Superior vena cava syndrome (SVCS) is an array of symptoms caused by the impairment of blood flow through the superior vena cava (SVC) to the right atrium. Symptoms that prompt suspicion of this syndrome include dyspnea, coughing, and swelling of the face, neck, upper trunk, and extremities. In rare instances, patients may complain of hoarseness, chest pain, dysphagia, and hemoptysis. Physical signs that may be noted on presentation are neck vein distention, thoracic vein distention, edema of the face or upper extremities, plethora, and tachypnea. Rarely, cyanosis, Horner syndrome, and a paralyzed vocal cord may also be present.
 
SVCS is usually a sign of locally advanced bronchogenic carcinoma. Survival depends on the status of the patient’s disease. When small cell bronchogenic carcinoma is treated with chemotherapy, the median survival times with or without SVCS are almost identical (42 weeks or 40 weeks, respectively). The 24-month survival rate is 9% in patients without SVCS and 3% in those with the syndrome. When the malignancy is treated with radiation therapy, 46% of patients who have non-small cell lung cancer experience relief of symptoms compared with 62% of patients who have small cell bronchogenic carcinoma. The 2-year survival rate of 5% is almost the same for both groups.
 
Most non-Hodgkin lymphoma patients with SVCS respond to appropriate chemotherapy or to combined modality regimens.  


==Etymology==
==Etymology==

Revision as of 00:13, 16 January 2009

Template:DiseaseDisorder infobox

WikiDoc Resources for Superior vena cava syndrome

Articles

Most recent articles on Superior vena cava syndrome

Most cited articles on Superior vena cava syndrome

Review articles on Superior vena cava syndrome

Articles on Superior vena cava syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Superior vena cava syndrome

Images of Superior vena cava syndrome

Photos of Superior vena cava syndrome

Podcasts & MP3s on Superior vena cava syndrome

Videos on Superior vena cava syndrome

Evidence Based Medicine

Cochrane Collaboration on Superior vena cava syndrome

Bandolier on Superior vena cava syndrome

TRIP on Superior vena cava syndrome

Clinical Trials

Ongoing Trials on Superior vena cava syndrome at Clinical Trials.gov

Trial results on Superior vena cava syndrome

Clinical Trials on Superior vena cava syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Superior vena cava syndrome

NICE Guidance on Superior vena cava syndrome

NHS PRODIGY Guidance

FDA on Superior vena cava syndrome

CDC on Superior vena cava syndrome

Books

Books on Superior vena cava syndrome

News

Superior vena cava syndrome in the news

Be alerted to news on Superior vena cava syndrome

News trends on Superior vena cava syndrome

Commentary

Blogs on Superior vena cava syndrome

Definitions

Definitions of Superior vena cava syndrome

Patient Resources / Community

Patient resources on Superior vena cava syndrome

Discussion groups on Superior vena cava syndrome

Patient Handouts on Superior vena cava syndrome

Directions to Hospitals Treating Superior vena cava syndrome

Risk calculators and risk factors for Superior vena cava syndrome

Healthcare Provider Resources

Symptoms of Superior vena cava syndrome

Causes & Risk Factors for Superior vena cava syndrome

Diagnostic studies for Superior vena cava syndrome

Treatment of Superior vena cava syndrome

Continuing Medical Education (CME)

CME Programs on Superior vena cava syndrome

International

Superior vena cava syndrome en Espanol

Superior vena cava syndrome en Francais

Business

Superior vena cava syndrome in the Marketplace

Patents on Superior vena cava syndrome

Experimental / Informatics

List of terms related to Superior vena cava syndrome

Cardiology Network

Discuss Superior vena cava syndrome further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Also known as: SVC syndrome

Overview

Superior vena cava syndrome (SVCS) is an array of symptoms caused by the impairment of blood flow through the superior vena cava (SVC) to the right atrium. Symptoms that prompt suspicion of this syndrome include dyspnea, coughing, and swelling of the face, neck, upper trunk, and extremities. In rare instances, patients may complain of hoarseness, chest pain, dysphagia, and hemoptysis. Physical signs that may be noted on presentation are neck vein distention, thoracic vein distention, edema of the face or upper extremities, plethora, and tachypnea. Rarely, cyanosis, Horner syndrome, and a paralyzed vocal cord may also be present.

SVCS is usually a sign of locally advanced bronchogenic carcinoma. Survival depends on the status of the patient’s disease. When small cell bronchogenic carcinoma is treated with chemotherapy, the median survival times with or without SVCS are almost identical (42 weeks or 40 weeks, respectively). The 24-month survival rate is 9% in patients without SVCS and 3% in those with the syndrome. When the malignancy is treated with radiation therapy, 46% of patients who have non-small cell lung cancer experience relief of symptoms compared with 62% of patients who have small cell bronchogenic carcinoma. The 2-year survival rate of 5% is almost the same for both groups.

Most non-Hodgkin lymphoma patients with SVCS respond to appropriate chemotherapy or to combined modality regimens.

Etymology

The Scottish obstetrician and anatomist, William Hunter, first described the entity in 1757, noting it as a complication of a syphilitic aortic aneurysm.

Epidemiology and Demographics

Most SVC syndromes in the present day are related to malignancy. An underlying malignancy is found in approximately 90% of patients.

Pathophysiology & Etiology

Collaterals form over time via the mammary, vertebrals, azygous and lateral thoracic veins, so despite almost or complete occlusion of the SVC venous drainage still can occur. Cerebral edema and obtundation with raised intracranial pressure is, therefore, rare. However, if this rare presentation is noted or if the airway is compromised, SVC syndrome represents a medical emergency.

Natural History

In the past, SVC syndrome was a medical emergency and empiric radiation was given to shrink the tumor. With the advent of better medical therapy for some lung cancers and lymphoma and the low morbidity associated with diagnostic procedures, this approach has fallen out of favor.

Signs and symptoms

The most common symptoms are these:

  • Dyspnea
  • Cough
  • Swollen face, neck, upper body, and arms.

Less common symptoms include the following:

  • Hoarse voice.
  • Chest pain.
  • Problems swallowing and/or talking.
  • Coughing up blood.
  • Swollen veins in the chest or neck.
  • Bluish color to the skin.
  • Drooping eyelid.
  • Headache
  • Facial plethora
  • Lightheadedness

Superior vena cava syndrome usually presents more gradually with an increase in symptoms over time as malignancies increase in size or invasiveness.[1]

Diagnosis

The current strategy is to embark on a search for the primary source of the tumor. Start with a chest x-ray as a screening tool followed by a CT scan with contrast to further define the anatomy, extent of compression and to guide biopsy if a diagnosis cannot be made less invasively, e.g. thoracentesis, sputum, lymph node, and bone marrow biopsy.

Differential Diagnosis

The leading cancers associated with SVC syndrome are bronchogenic lung cancer (particularly small cell lung cancer), breast cancer, and lymphoma.

Benign causes of SVC syndrome include mediastinal fibrosis, histoplasmosis, radiation therapy complications, retrosternal goiter, Behcet’s syndrome, and thrombosis due to indwelling catheters or pacemakers. In the past, Tuberculosis and Syphilis were major players.

History and Symptoms

The presentation depends on the degree of occlusion and the rapidity with which it develops. The most common symptoms are dyspnea, facial swelling/fullness (suffusion) and cough. The most common signs are venous distention of the neck and chest wall and facial edema. Less commonly, chest pain, dysphagia, proptosis, hemoptysis, glossal edema, hoarseness, and headache are described. Symptoms get worse with leaning forward, coughing or lying down. Typically symptoms are present for >3 months before diagnosis.

Physical Examination

Appearance of the Patient

Pemberton’s Sign: suffusion, plethora, or duskiness that develop upon elevation of the arms above the head in patients with SVC syndrome.

Vital Signs

Skin

The skin of the face may have plethora.

There may be distension of veins on the torso.

Ear Nose and Throat

There is swelling of the face.

Laboratory Findings

Chest X Ray

This is a useful test to exclude lung cancer

MRI and CT

Useful in evaluating source and extent of a neoplasm.

Other Diagnostic Studies

Biopsy may be neccessary to evaluate the underlying cause.

Risk Stratification and Prognosis

SVC syndrome is rarely fatal, and the prognosis is generally related to the prognosis of the underlying malignancy rather than the presence/absence of venous obstruction.

Treatment

Pharmacotherapy

Acute Pharmacotherapies

The goal of therapy is to relieve the obstructive symptoms and address the underlying process. Removal of nonessential central lines and upright posture are initial measures. Diuretics, steroids, radiation and chemotherapy are used depending on clinical scenario. In the case of compression, anticoagulation and stent placement are accepted means of attempting to assure long-term patency and prevent propagation. [2] [3] [4]

Surgery and Device Based Therapy

Stenting may be neccessary to preserve patency.

References

  1. Beeson, Michael S. "Superior Vena Cava Syndrome". Retrieved 2008-03-24.
  2. Nieto AF, Doty DB. Superior vena cava obstruction: clinical syndrome, etiology, and treatment. Curr Probl Cancer 1986; 10:441-84.
  3. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome. The myth--the facts. Am Rev Respir Dis 1990; 141:1114-8.
  4. Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990; 160:207-11.

See also

Acknowledgements

Source of Initial Content: Morning report notes prepared by Dr. Duane Pinto, C. Michael Gibson, M.S., M.D.

Template:SIB

Template:WikiDoc Sources